Sympathetic blockade prevents the decrease in cardiac VEGF expression and capillary supply in experimental renal failure

American Journal of Physiology - Renal Physiology

Volumn 300, Issue 1, 2011, Pages

  Amann, K ^a   Odoni, G ^b   Benz, K ^a   Campean, V ^a   Jacobi, J ^a   Hilgers, K F ^a   Hartner, A ^a   Veelken, R ^a   Orth, S R ^c,d  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Ospedale di Dolo   (Italy)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d Dialysis Centre Bad Aibling   (Germany)

Author keywords

Capillary supply; Capillary myocyte mismatch; Chronic renal failure; Renal denervation; Sympathetic nervous system; Uremic cardiomyopathy; Vascular endothelial growth factor

Indexed keywords

MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HEART MUSCLE CAPILLARY; KIDNEY DENERVATION; KIDNEY FAILURE; MALE; MORPHOLOGY; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SENSORY NERVE; SYMPATHETIC BLOCKING; SYMPATHETIC TONE;

EID: 78651299908     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00363.2010     Document Type: Article

References (42)

1. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 9: 1018-1022, 1998.
2. Amann K, Buzello M, Simonaviciene A, Miltenberger-Miltenyi G, Koch A, Nabokov A, Gross ML, Gless B, Mall G, Ritz E. Capillary/myocyte mismatch in the heart in renal failure - a role for erythropoietin? Nephrol Dial Transplant 15: 964-969, 2000.
3. Amann K, Faulhaber J, Campean V, Balajew V, Dono R, Mall G, Ehmke H. Impaired myocardial capillarogenesis and increased adaptive capillary growth in FGF2-deficient mice. Lab Invest 86: 45-53, 2006.
4. Amann K, Hofstetter J, Campean V, Koch A, Gross ML, Veelken R, Ritz E. Nonhypotensive dose of beta-adrenergic blocker ameliorates capillary deficits in the hearts of rats with moderate renal failure. Virchows Arch 449: 207-214, 2006.
5. Amann K, Hofstetter J, Campean V, Koch A, Gross ML, Veelken R, Ritz E. Nonhypotensive dose of beta-adrenergic blocker ameliorates capillary deficits in the hearts of rats with moderate renal failure. Virchows Arch 449: 207-214, 2006.
6. Amann K, Kronenberg G, Gehlen F, Wessels S, Orth S, Munter K, Ehmke H, Mall G, Ritz E. Cardiac remodelling in experimental renal failure-an immunohistochemical study. Nephrol Dial Transplant 13: 1958-1966, 1998.
7. Amann K, Munter K, Wessels S, Wagner J, Balajew V, Hergenroder S, Mall G, Ritz E. Endothelin A receptor blockade prevents capillary/myocyte mismatch in the heart of uremic animals. J Am Soc Nephrol 11: 1702-1711, 2000.
8. Amann K, Neimeier KA, Schwarz U, Tornig J, Matthias S, Orth SR, Mall G, Ritz E. Rats with moderate renal failure show capillary deficit in heart but not skeletal muscle. Am J Kidney Dis 30: 382-388, 1997.
9. Amann K, Ritz E. The heart in renal failure: morphological changes of the myocardiom - new insights. J Clin Basic Cardiol 4: 109-113, 2001.
10. Amann K, Ritz E. Reduced cardiac ischaemia tolerance in uraemia - what is the role of structural abnormalities of the heart? Nephrol Dial Transplant 11: 1238-1241, 1996.
11. Amann K, Veelken R. Mechanisms and consequences of sympathetic hyperactivity in renal disease. Clin Nephrol 60, Suppl 1: S81-S92, 2003.
12. Amann K, Wiest G, Zimmer G, Gretz N, Ritz E, Mall G. Reduced capillary density in the myocardium of uremic rats-a stereological study. Kidney Int 42: 1079-1085, 1992.
13. Campean V, Karpe B, Haas C, Atalla A, Peters H, Rupprecht H, Liebner S, Acker T, Plate K, Amann K. Angiopoietin 1 and 2 gene and protein expression is differentially regulated in acute anti-Thy1.1 glomerulonephritis. Am J Physiol Renal Physiol 294: F1174-F1184, 2008.
14. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 25: 878-882, 1995.
15. Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis 26: 861-865, 1995.
16. Campese VM, Krol E. Neurogenic factors in renal hypertension. Curr Hypertens Rep 4: 256-260, 2002.
17. Castagno D, Jhund PS, McMurray JJ, Lewsey JD, Erdmann E, Zannad F, Remme WJ, Lopez-Sendon JL, Lechat P, Follath F, Hoglund C, Mareev V, Sadowski Z, Seabra-Gomes RJ, Dargie HJ. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. Eur J Heart Fail 12: 607-616, 2010.
18. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327: 1912-1918, 1992.
19. Di Marco GS, Reuter S, Hillebrand U, Amler S, Konig M, Larger E, Oberleithner H, Brand E, Pavenstadt H, Brand M. The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol 20: 2235-2245, 2009.
20. Dikow R, Kihm LP, Zeier M, Kapitza J, Tornig J, Amann K, Tiefenbacher C, Ritz E. Increased infarct size in uremic rats: reduced ischemia tolerance? J Am Soc Nephrol 15: 1530-1536, 2004.
21. Ditting T, Tiegs G, Veelken R. Autonomous innervation in renal inflammatory disease-innocent bystander or active modulator? J Mol Med 87: 865-870, 2009.
22. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int 54: 1720-1725, 1998.
23. Haas CS, Campean V, Kuhlmann A, Dimmler A, Reulbach U, Forster C, Aigner T, Acker T, Plate K, Amann K. Analysis of glomerular VEGF mRNA and protein expression in murine mesangioproliferative glomerulonephritis. Virchows Arch 450: 81-92, 2007.
24. Hampl H, Hennig L, Rosenberger C, Amirkhalily M, Gogoll L, Riedel E, Scherhag A. Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients. Am J Nephrol 25: 211-220, 2005.
25. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH. Sympathetic nerve activity in end-stage renal disease. Circulation 106: 1974-1979, 2002.
26. Henquell L, Honig CR. Intercapillary distances and capillary reserve in right and left ventricles: significance for control of tissue po2. Microvasc Res 12: 35-41, 1976.
27. Jacobi J, Porst M, Cordasic N, Namer B, Schmieder RE, Eckardt KU, Hilgers KF. Subtotal nephrectomy impairs ischemia-induced angiogenesis and hindlimb re-perfusion in rats. Kidney Int 69: 2013-2021, 2006.
28. Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 14: 3239-3244, 2003.
29. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 12: 2427-2433, 2001.
30. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffelen AC, Koomans HA. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 340: 1321-1328, 1999.
31. Mallamaci F, Benedetto FA, Tripepi G, Cutrupi S, Pizzini P, Stancanelli B, Seminara G, Bonanno G, Rapisarda F, Fatuzzo P, Malatino LS, Zoccali C. Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients. J Hypertens 26: 1875-1882, 2008.
32. Mattfeldt T, Mall G, Gharehbaghi H, Moller P. Estimation of surface area and length with the orientator. J Microsc 159: 301-317, 1990.
33. Nabokov AV, Amann K, Wessels S, Munter K, Wagner J, Ritz E. Endothelin receptor antagonists influence cardiovascular morphology in uremic rats. Kidney Int 55: 512-519, 1999. (Pubitemid 29082877)
34. Odoni G, Ogata H, Viedt C, Amann K, Ritz E, Orth SR. Cigarette smoke condensate aggravates renal injury in the renal ablation model. Kidney Int 61: 2090-2098, 2002.
35. Silberberg J, Racine N, Barre P, Sniderman AD. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 6: 1-4, 1990.
36. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36: 286-290, 1989.
37. Tiegs G, Bang R, Neuhuber WL. Requirement of peptidergic sensory innervation for disease activity in murine models of immune hepatitis and protection by beta-adrenergic stimulation. J Neuroimmunol 96: 131-143, 1999.
38. Tomanek RJ. Selective effects of alpha-methyldopa on myocardial cell components independent of cell size in normotensive and genetically hypertensive rats. Hypertension 4: 499-506, 1982.
39. Tomanek RJ. Sympathetic nerves modify mitochondrial and capillary growth in normotensive and hypertensive rats. J Mol Cell Cardiol 21: 755-764, 1989.
40. Tornig J, Amann K, Ritz E, Nichols C, Zeier M, Mall G. Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure:the effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 7: 667-675, 1996.
41. Welten GM, Chonchol M, Hoeks SE, Schouten O, Bax JJ, Dunkelgrun M, van Gestel YR, Feringa HH, van Domburg RT, Poldermans D. Beta-blockers improve outcomes in kidney disease patients having noncardiac vascular surgery. Kidney Int 72: 1527-1534, 2007.
42. Ye S, Gamburd M, Mozayeni P, Koss M, Campese VM. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 11: 723-728, 1998.